South Korea’s Chong Kun Dang Pharmaceutical Corp. (CKD) announced on Monday the completion of a phase III study of anacetrapib, MSD’s investigational dyslipidemia drug, raising the likelihood of early market launching of its own investigational molecule CKD-519 in the same class.
Earlier, MSD announced preliminary data from the phase III study of anacetrapib showed a reduction in myocardial infarction with an acceptable safety profile. The new drug inhibits cholesterol ester transfer protein (CETP) that could lower bad cholesterol known as LDLC and triglyceride while increasing good cholesterol HDLC.
Several multinational pharmaceutical companies had attempted to develop a CETP inhibitor that differentiates itself from statins that lowers only LDLC, but they failed. CKD’s investigational drug is similar to anacetrapib in mechanism of action and chemical properties. Currently, MSD, CKD and Amgen are developing a CETP inhibitor.
By Kim Hye-soon
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]